<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00598624</url>
  </required_header>
  <id_info>
    <org_study_id>2005-005182-11</org_study_id>
    <nct_id>NCT00598624</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)</brief_title>
  <acronym>AlloTreo</acronym>
  <official_title>Clinical Phase II Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Haematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentric, non-randomized, non-controlled open-label phase II trial to evaluate
      the safety and efficacy of treosulfan in a combination regimen with fludarabine as
      conditioning therapy prior to allogeneic stem cell transplantation (SCT) in patients with
      haematological malignancies.

      The aim is to demonstrate a clinical benefit compared with historical data on intravenous
      busulfan (BusulfexTM, BusilvexTM), the only drug so far registered in the indication
      conditioning before allogeneic stem cell transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Evaluation of engraftment</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Evaluation of the incidence of CTC grade 3 and 4 adverse events</measure>
    <time_frame>between day -6 and day +28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Evaluation of disease free survival (DFS)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Evaluation of overall survival (OS)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Evaluation of relapse incidence (RI)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Documentation of donor chimerism</measure>
    <time_frame>on day +28, +56 and +100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Evaluation of incidence of non-relapse mortality (NRM)</measure>
    <time_frame>on day +28 and day +100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: cumulative incidence of NRM</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Evaluation of cumulative incidence and severity of acute and chronic graft vs. host disease (GvHD)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: EBV reactivation</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Leukemia</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Diffuse Large Cell Lymphoma</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan IV</intervention_name>
    <description>Treosulfan i.v.: 14 g/mÂ²/d from day -6 to day -4</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with haematological malignancies, according to WHO classification, such as:

               -  acute myeloid leukaemia -AML- in CR1 except &quot;low-risk cases&quot; defined by t(15;17),
                  t(8;21), inv 16 or normal cytogenetics at diagnosis with FLT3-ITD negative and
                  NPM-1 positive, with no high risk clinical criteria

               -  any AML beyond CR1

               -  acute lymphoblast leukaemia -ALL- in CR1 only if at &quot;high risk&quot; defined by
                  cytogenetics as t(9;22), t(4;11) or for persistence of minimal residual disease
                  (MRD)

               -  any ALL beyond CR1

               -  chronic myeloid leukaemia -CML- in chronic phase (CP) or accelerated phase (AP)
                  intolerant/not responsive to TK-inhibitors

               -  myeloproliferative disorders -MPD-

               -  myelodysplastic syndrome -MDS- with intermediate or high risk International
                  Prognostic Scoring System (IPSS)

               -  diffuse large cell lymphoma -DLCL- with a chemosensitive relapse or beyond CR1

               -  lymphoblastic and Burkitt lymphoma with a chemosensitive relapse or beyond CR1

               -  mantle cell lymphoma -MCL- with a chemosensitive relapse or beyond CR1

               -  follicular lymphoma -FCL- with a chemosensitive relapse or beyond CR2

               -  Hodgkin lymphoma -HD- with a chemosensitive relapse or beyond CR1

               -  chronic lymphocytic leukaemia -CLL- at &quot;poor risk&quot; in CR1 or with a
                  chemosensitive relapse

               -  CLL relapsing after high dose chemotherapy

               -  T-cell non Hodgkin lymphoma -T-NHL- in CR1 or beyond

               -  multiple myeloma -MM- at high risk for cytogenetics or ISS stage 3 in CR1
                  following high dose chemotherapy

               -  MM at any relapse/progression except refractory disease

          2. Availability of an HLA-identical sibling donor (MRD) or HLA-identical unrelated donor
             (MUD)

               -  HLA-identity defined by the following markers: A, B, DRB1, DQB1 or a single or
                  double Cord Blood unit (CB) with at least a 4 out of 6 HLA-matching by the
                  following markers: A, B and DRB.

             A) identity between the 2 CB units and the recipient;

             B) Two identical CB units with one or two mismatches with the recipient;

             C) Two CB units with one mismatch between them and two mismatches with the recipient.
             We will prefer mismatches either for class I or for class II antigens; we will avoid
             mismatches concerning both classes I and II together.

          3. Target graft size (unmanipulated, preferably not cryopreserved)

               -  bone marrow: 2 to 10 x 106 CD34+ cells/kg BW recipient or &gt; 2 x 108 nucleated
                  cells/kg BW recipient or

               -  peripheral blood: 4 to 10 x 106 CD34+ cells/kg BW recipient

          4. Age &gt; 18 and &lt; 70 years

          5. Karnofsky Index &gt; 80 %

          6. Adequate contraception in female patients of child-bearing potential

          7. Written informed consent

        Exclusion Criteria:

          1. Secondary malignancies

          2. Previous allogeneic transplantation

          3. Hematopoietic cell transplantation-specific comorbidity index &gt; 4 (HCT-CI Sorror et
             al, Appendix M)

          4. Known and manifested malignant involvement of the CNS

          5. Active infectious disease

          6. HIV- positivity or active hepatitis infection

          7. Impaired liver function (Bilirubin &gt; upper normal limit; Transaminases &gt; 3.0 x upper
             normal limit)

          8. Impaired renal function (Creatinine-clearance &lt; 60 ml/min; Serum Creatinine &gt; 1.5 x
             upper normal limit).

          9. Pleural effusion or ascites &gt; 1.0 L

         10. Pregnancy or lactation

         11. Known hypersensitivity to treosulfan and/or fludarabine

         12. Participation in another experimental drug trial within 4 weeks before day -6

         13. Non-co-operative behaviour or non-compliance

         14. Psychiatric diseases or conditions that might impair the ability to give informed
             consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabio FC Ciceri, MD</last_name>
    <role>Study Director</role>
  </overall_official>
  <overall_contact>
    <last_name>Luciano LC Callegaro, Monitor</last_name>
    <phone>+390226433903</phone>
    <email>callegaro.luciano@hsr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefania ST Trinca, Data Manager</last_name>
    <phone>+390226433903</phone>
    <email>trinca.stefania@hsr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ematologia, Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>Foggia</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelo Michele Carella, MD</last_name>
      <email>am.carella@operapadrepio.it</email>
    </contact>
    <contact_backup>
      <last_name>Marzia Tricarico, DM</last_name>
      <email>m.tricarico@operapadrepio.it</email>
    </contact_backup>
    <investigator>
      <last_name>Nicola Cascavilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele; UnitÃ  Operativa di Ematologia</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Crotta, MD</last_name>
      <phone>+39 0226433903</phone>
      <email>a.crotta@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>Stefania Trinca</last_name>
      <phone>+39 0226434289</phone>
      <email>stefania.trinca@hsr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Jacopo Peccatori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Ematologia, Ospedali Riuniti</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Grassi, MD</last_name>
      <email>agrassi@ospedaliriuniti.bergamo.it</email>
    </contact>
    <contact_backup>
      <last_name>Maria Luisa Ferrari, DM</last_name>
      <email>mlferrari@ospedaliriuniti.bergamo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Alessandro Rambaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale centrale di Bolzano - Reparto di Ematologia</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Morello, MD</last_name>
      <phone>+390471908807</phone>
      <email>enrico.morello@asbz.it</email>
    </contact>
    <investigator>
      <last_name>Enrico Morello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PO &quot;R.Binaghi&quot; - CTMO</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriana Vacca, MD</last_name>
      <phone>+393285452813</phone>
      <email>vaadriana@tiscali.it</email>
    </contact>
    <investigator>
      <last_name>Giorgio La Nasa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO &quot;Santa Croce&quot; e Carle - Reparto di Ematologia</name>
      <address>
        <city>Cuneo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Bertolotti, Data Manager</last_name>
      <phone>+390171642229</phone>
      <email>laura.bertolotti@libero.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Gallamini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia - Divisione di Ematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liliana Calabrese, Data Manager</last_name>
      <phone>+390257489536</phone>
      <email>liliana.calabrese@ieo.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Martinelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile - UTI ematologia per il trapianto emopoietico</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Di Bartolomei, MD</last_name>
      <email>pescaratmo@virgilio.it</email>
    </contact>
    <investigator>
      <last_name>Paolo Di Bartolomei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova - SC di Ematologia</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Bonini, MD</last_name>
      <email>bonini.alessandro@asmn.re.it</email>
    </contact>
    <investigator>
      <last_name>Luigi Gugliotta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento Biotecnologie Cellulari ed Ematologia; Azienda Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilia Iannella, MD</last_name>
      <phone>+39 3202233365</phone>
      <email>emiliaiannella@libero.it</email>
    </contact>
    <contact_backup>
      <last_name>Roberto Ricci</last_name>
      <phone>+39 3477578735</phone>
      <email>r.ricci@bce.uniroma1.it</email>
    </contact_backup>
    <investigator>
      <last_name>Roberto Foa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO San Camillo Forlanini - UOC ematologia e trapianto</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatrice Pinazzi, MD</last_name>
      <email>mpinazzi@scamilloforlanini.rm.it</email>
    </contact>
    <investigator>
      <last_name>Ignazio Majolino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Santa Maria della Misericordia - Clinica Ematologica</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Patriarca, MD</last_name>
      <email>patriarca.francesca@aoud.sanita.fvg.it</email>
    </contact>
    <investigator>
      <last_name>Michela Cerno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>January 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2008</study_first_posted>
  <last_update_submitted>August 10, 2009</last_update_submitted>
  <last_update_submitted_qc>August 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2009</last_update_posted>
  <responsible_party>
    <name_title>Fabio Ciceri, MD</name_title>
    <organization>IRCCS San Raffaele</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treosulfan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 5, 2017</submitted>
    <returned>April 12, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

